Linee guida SISET in Ostetricia e Ginecologia - Terapia compressiva

18
71. Grandone E, Margaglione M, Colaizzo D, D'Andrea G, Cappucci
G, Brancaccio V, et al. Genetic susceptibility to pregnancy-related
venous thromboembolism: roles of factor V
Leiden, prothrombin G20210A, and methylenetetrahydrofolate
reductase C677T mutations. Am J Obstet Gynecol
1998;179:1324-8.
72. Martinelli I, Legnani C, Bucciarelli P, Grandone E, De Stefano
V, Mannucci PM. Risk of pregnancy-related venous thrombosis
in carriers of severe inherited thrombophilia. Thromb
Haemost 2001;86:800-3.
73. Brill-Edwards P, Ginsberg JS, Gent M, Hirsh J, Burrows R,
Kearon C, et al. Safety of withholding heparin in pregnant
women with a history of venous thromboembolism. Recurrence
of Clot in This Pregnancy Study Group. N Engl J Med
2000;343:1439-44.
74. Brenner B. Inherited thrombophilia and pregnancy loss.
Thromb Haemost 1999;82:634-40.
75. Brenner B, Blumenfeld Z. Thrombophilia and fetal loss. Blood
Rev 1997;11:72-9.
76. Cook CL, Pridham DD. Recurrent pregnancy loss. Curr Opin
Obstet Gynecol 1995;7:357-66.
77. Hatasaka HH. Recurrent miscarriage: Epidemiologic factors,
definitions, and incidence. Clin Obstet Gynecol 1994;37:625-
34.
78. Raziel A, Arieli S, Bukovsky I, Caspi E, Golan A. Investigation
of the uterine cavity in recurrent aborters. Fertil Steril 1994;
62:1080-2.
79. Beressi AH, Tefferi A, Silverstein MN, Petitt RM, Hoagland
WC. Outcome analysis of 34 pregnancies in women with
essential thrombocythemia. Arch Intern Med 1995;155:1217-
22.
80. Sanson BJ, Friederich PW, Simioni P, Zanardi S, Hilsman MV,
Girolami A, et al. The risk of abortion and stillbirth in
antithrombin-, protein C-, and protein S-deficient women.
Thromb Haemost 1996;75:387-8.
81. Preston FE, Rosendaal FR, Walker ID, Briet E, Berntorp E,
Conard J, et al. Increased fetal loss in women with heritable
thrombophilia. Lancet 1996;348:913-6.
82. Ridker PM, Miletich JP, Buring JE, Ariyo AA, Price DT, Manson
JE, et al. Factor V Leiden mutation as a risk factor for recurrent
pregnancy loss. Ann Intern Med 1998;128:1000-3.
83. Grandone E, Margaglione M, Colaizzo D, d'Addedda M, Cappucci
G, Vecchione G, et al. Factor V Leiden is associated with
repeated and recurrent unexplained fetal losses. Thromb
Haemost 1997;77:822-4.
84. Brenner B, Sarig G, Weiner Z, Younis J, Blumenfeld Z, Lanir N.
Thrombophilic polymorphisms in women with fetal loss.
Thromb Haemost 1999;82:6-9.
85. Wramsby ML, Sten-Linder M, Bremme K. Primary habitual
abortions are associated with high frequency of Factor V Leiden
mutation. Fertil Steril 2000;74:987-91.
86. Foka ZJ, Lambropoulos AF, Saravelos H, Karas GB, Karavida A,
Agorastos T, et al. Factor V leiden and prothrombin G20210A
mutations, but not methylenetetrahydrofolate reductase
C677T, are associated with recurrent miscarriages. Hum
Reprod 2000;15:458-62.
87. Gris JC, Quere I, Monpeyroux F, Mercier E, Ripart-Neveu S,
Tailland ML, et al. Case-control study of the frequency of
thrombophilic disorders in couples with late foetal loss and
no thrombotic antecedent--the Nimes Obstetricians and
Haematologists Study5 (NOHA5). Thromb Haemost 1999;81:
891-9.
88. Pickering W, Holmes Z, Regan L, Cohen H. Normal prevalence
of the G20210A prothrombin gene mutation in women with
recurrent miscarriage. Br J Haematol 1998;102:250.
89. Martinelli I, Taioli E, Cetin I, Marinoni A, Gerosa S, Villa MV,
et al. Mutations in coagulation factors in women with unexplained
late fetal loss. N Engl J Med 2000;343:1015-8.
90. Nelen WL, Blom HJ, Thomas CM, Steegers EA, Boers CH, Eskes
TK. Methylenetetrahydrofolate reductase polymorphism
affects the change in homocysteine and folate concentrations
resulting from low dose folic acid supplementation in
women with unexplained recurrent miscarriages. J Nutr
1998;128:1336-41.
91. Deitcher SR, Park VM, Kutteh WH. Methylene tetrahydrofolate
reductase 677C®T mutation analysis in Caucasian women
haematologica vol. 87(supplement to n. 12):2002
E. Grandone et al.
with early first trimester recurrent pregnancy loss. Blood
1998; 92 Suppl 1:117b.
92. Zöller B, Berntsdotter A, Garcia de Frutos P, Dahlback B. Resistance
to activated protein C as an additional genetic risk factor
in hereditary deficiency of protein S. Blood 1995;85:3518-
23.
93. Brenner B, Zivelin A, Lanir N, Greengard JS, Griffin JH, Seligsohn
U. Venous thromboembolism associated with double
heterozygosity for R506Q mutation of factor V and for T298M
mutation of protein C in a large family of previously described
homozygous protein C deficient newborn with massive
thrombosis. Blood 1996;88:877-80.
94. Mandel H, Brenner B, Berant M, Rosenberg N, Lanir N, Jakobs
C, et al. Coexistence of hereditary homocystinuria and factor
V Leiden: effect on thrombosis. N Engl J Med 1996;334:763-
8.
95. Brenner B, Vulfsons SL, Lanir N, Nahir M. Coexistence of
familial antiphospholipid syndrome and factor V Leidenimpact
on thrombotic diathesis. Br J Haematol 1996;94:166-
7.
96. Redman CW. Current topic: pre-eclampsia and the placenta.
Placenta 1991;12:301-8.
97. Redman CW. Platelets and the beginning of pre-eclampsia. N
Engl J Med 1990;323:478-80.
98. Dizon-Townson DS, Nelson LM, Easton K, Ward K. The factor
V Leiden mutation may predispose women to severe
preeclampsia. Am J Obstet Gynecol 1996;175:902-5.
99. Grandone E, Margaglione M, Colaizzo D, Cappucci G, Paladini
D, Martinelli P, et al. Factor V Leiden, C→T MTHFR polymorphism
and genetic susceptibility to preeclampsia. Thromb
Haemost 1997;77:1052-4.
100. Kupferminc MJ, Eldor A, Steinman N, Many A, Bar-Am A, Jaffa
A, et al. Increased frequency of genetic thrombophilia in
women with complications of pregnancy. N Engl J Med
1999;340:9-13
101. Brenner B, Lanir N, Thaler I. HELLP syndrome associated with
factor V R506Q mutation. Br J Haematol 1996;92:999-1001.
102. Krauss T, Augustin HG, Osmers R, Meden H, Unterhalt M, Kuhn
W. Activated protein C resistance and factor V Leiden in
patients with hemolysis, elevated liver enzymes, low platelets
syndrome. Obstet Gynecol 1998;92:457-60.
103. Wiener-Megnagi Z, Ben-Shlomo I, Goldberg Y, Shalev E.
Resistance to activated protein C and the Leiden mutation:
high prevalence in patients with abruptio placentae. J Obstet
Gynecol 1998;179:1565-7.
104. De Vries JIP, Dekker GA, Huijgens PC, Jakobs C, Blomberg BM,
van Geijn HP. Hyperhomocysteinaemia and protein S deficiency
in complicated pregnancies. Br J Obstet Gynaecol
1997;104:1248-54.
105. Goddijn-Wessel TA, Wouters MG, van de Molen EF, Spuijbroek
MD, Steegers-Theunissen RP, Blom HJ, et al. Hyperhomocysteinemia:
a risk factor for placental abruption or infarction.
Eur J Obstet Gynecol Reprod Biol 1996;66:23-9.
106. Wilson WA, Gharavi AE, Koike T. International Consensus
Statement on preliminary classification criteria for definite
antiphospholipid syndrome. Arthritis Rheum 1998;42:1309-
11.
107. Harris EN, Spinnato JA. Should anticardiolipin tests be performed
in otherwise healthy pregnant women? Am J Obstet
Gynecol 1991;165:1272-7.
108. Lockwood CJ, Romero R, Feinberg RF, Clyne LP, Coster B, Hobbins
JC. The prevalence and biologic significance of lupus
anticoagulant and anticardiolipin antibodies in a general
obstetric population. Am J Obstet Gynecol 1989;161:369-73.
109. Rix P, Stentoft J, Aunsholt NA, Dueholm M, Tilma KA, Hoier-
Madsen M. Lupus anticoagulant and anticardiolipin antibodies
in an obstetric population. Acta Obstet Gynecol Scand
1992; 71:605-9.
110. Lynch A, Marler R, Murphy J, Davila G, Santos M, Rutledge J,
Emlen W. Antiphospholipid antibodies in predicting adverse
pregnancy outcome. A prospective study. Ann Intern Med
1994;120:470-5.
111. Infante-Rivard C, David M, Gauthier R, Rivard GE. Lupus anticoagulants,
anticardiolipin antibodies, and fetal loss. A casecontrol
study. N Engl J Med 1991;325:1063-6.
112. Haddow JE, Rote NS, Dostal-Johnson D, Palomaki GE, Pulkki-